预约演示
更新于：2025-09-13
Methohexital Sodium
美索比妥
更新于：2025-09-13
概要
基本信息
药物类型 小分子化药 |
别名 (±)-5-allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid、5-allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione、5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione + [8] |
作用方式 拮抗剂 |
作用机制 GABAA receptor拮抗剂(γ-氨基丁酸 A 受体拮抗剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1960-06-27), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H18N2NaO3 |
InChIKeyZNCHEYWRDOJPAW-UHFFFAOYSA-N |
CAS号309-36-4 |
关联
6
项与 美索比妥 相关的临床试验NCT05655754
A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy
NCT04187196
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
NCT02624050
Comparison of Methohexital With Propofol for Anesthetic Induction in Patients Treated With an Antagonist of the Renin-Angiotensin System.
100 项与 美索比妥 相关的临床结果
登录后查看更多信息
100 项与 美索比妥 相关的转化医学
登录后查看更多信息
100 项与 美索比妥 相关的专利（医药）
登录后查看更多信息
1,621
项与 美索比妥 相关的文献（医药）2025-08-01A&A practice
Inadvertent Intra-Arterial Methohexital Injection During Procedural Sedation: A Case Report and Contemporary Perspective.
Article
作者: Brucks, Eric ; Obagi, Sabine ; Baskin, David
Barbiturates have historically played a significant role in clinical anesthesia and sedation, accompanied by a variety of medication use warnings. Early case reports discussed severe complications of accidental intra-arterial injections of certain barbiturates, including thrombosis progressing to tissue necrosis and gangrene. While management strategies have been explored, no contemporary recommendations are available in the literature. Following a recent case of intra-arterial methohexital administration during electroconvulsive therapy (ECT), we propose a protocol that includes early use of subcutaneous enoxaparin at standard prophylactic dosing, warm compresses, and close neurovascular monitoring to reduce thrombotic complications and prevent progression to tissue damage.
2025-08-01ACTA ANAESTHESIOLOGICA SCANDINAVICA
Propofol Versus Methohexital in Electroconvulsive Therapy: Impact on Treatment Efficacy and Adverse Effects. A Systematic Literature Review and Meta‐Analysis
Review
作者: Huoponen, Saara H. ; Sisa, Katrin ; Ahlmén‐Laiho, Ulla ; Saari, Tom ; Taittonen, Markku
ABSTRACT:
Background:
Electroconvulsive therapy (ECT) is a widely used treatment for depression, but the choice of the anesthetic that is used for induction may affect both clinical outcomes and the occurrence of adverse effects (AEs). Propofol and methohexital are frequently used in Finland, yet their relative impact on treatment efficacy and AEs remains uncertain.
Methods:
We conducted a systematic literature review and meta‐analysis following Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. Electronic databases were searched up to January 21, 2025. Studies comparing propofol and methohexital in adult patients receiving ECT for depression and utilizing numeric scales for depression assessment were included. The primary outcome was the clinical treatment response, defined by the number of ECT sessions required to achieve remission. The secondary outcome was the variation of AEs associated with ECT between comparator groups.We included eight studies in the final analysis with 194 patients in the propofol group and 198 patients in the methohexital group. Five of the studies were randomized controlled trials and three were retrospective cohort studies. Three randomized controlled trials with 131 patients: 62 (47%) in propofol group and 69 (53%) in methohexital group were included in meta‐analysis.
Results:
The number of ECT sessions required for recovery did not differ between groups. All studies demonstrated effective alleviation of depression through ECT, regardless of anesthetic choice. However, AEs were inconsistently reported, and a comprehensive overview of the topic was not possible.
Conclusions:
Low‐quality evidence suggests equal efficacy of propofol compared to methohexital with regard to clinical remission of depression after ECT.
Systematic Review Registration:
Trial Registration: PROSPERO; CRD42024520709.
Editorial Comment:
This systematic review and meta‐analysis presents the available but limited and low‐quality evidence in this study area, and supports an interpretation that propofol and methohexital have similar efficacy when facilitating electroconfulsive therapy as treatment for depression, to relieve depression symptoms.
2025-06-01JOURNAL OF ECT
A Survey of ECT Anesthesia Practice Variation in Finland
Article
作者: Sisa, Katrin ; Huoponen, Saara H. ; Taittonen, Markku ; Saari, Tom ; Ahlmén-Laiho, Ulla ; Huoponen, Saara H
Objective:
This study examines the extent of variation in anesthesia practices among Finnish neuromodulation units providing electroconvulsive therapy (ECT) and investigates recent changes within individual units.
Methods:
An electronic survey was carried out among Finnish neuromodulation units exploring staff demographics, anesthesia practices (including agents and adjuvants), patient physiology monitoring, observed adverse effects, patient follow-up times, and recent anesthesia protocol changes.
Results:
Finland has 26 neuromodulation units providing ECT, of which 18 (69%) responded to our study. The research uncovered significant differences in anesthesia practices, including induction agent choice, convulsion motor component monitoring, staff educational backgrounds, and reported adverse effects. Propofol was the most commonly used anesthetic in 14 units (78%). Three units (17%) reported using methohexital in 80%–100% of their patients, whereas in contrast, methohexital was not used at all in 10 units (56%). Electromyography seizure activity was quantitatively measured in 6 units (33%), whereas 10 units (56%) did not measure electromyography seizure activity at all. The remaining 2 units assessed seizure activity through visual observation. Headache requiring medication was the most commonly reported adverse effect, and it was reported as a frequent problem in 3 units (18%).
Conclusions:
Based on the variation in anesthesia practices identified in the study, we suggest there may be benefits to developing a national guideline for standardizing treatment.
1
项与 美索比妥 相关的新闻（医药）2024-09-20
·药闻康策
100 项与 美索比妥 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1960-06-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 73 | (Sedation With Propofol Group) | 蓋簾獵衊網鑰夢廠鹹積(鹹鏇夢範淵鏇網網願獵) = 醖遞衊鑰簾網簾襯蓋窪 糧鑰遞夢糧觸蓋積窪窪 (製壓鏇製蓋鏇廠夢壓艱, 選築醖顧遞淵顧製餘製 ~ 願築網艱顧餘願願糧廠) 更多 | - | 2023-11-13 | ||
(Sedation With Methohexital Group) | 蓋簾獵衊網鑰夢廠鹹積(鹹鏇夢範淵鏇網網願獵) = 構鹹鹹鹽夢齋醖簾範鏇 糧鑰遞夢糧觸蓋積窪窪 (製壓鏇製蓋鏇廠夢壓艱, 艱簾艱糧壓製淵醖築構 ~ 構鹽網範顧衊繭淵壓積) 更多 | ||||||
临床4期 | 73 | 築獵鏇網觸遞築鏇衊製(膚願鏇餘膚窪膚範鏇窪) = 壓簾齋蓋遞夢鏇鹽蓋鹽 齋觸壓網鬱範築積願壓 (艱壓壓鹽選窪鬱窪窪願 ) 更多 | - | 2022-09-21 | |||
築獵鏇網觸遞築鏇衊製(膚願鏇餘膚窪膚範鏇窪) = 餘選簾鬱遞糧鏇製遞顧 齋觸壓網鬱範築積願壓 (艱壓壓鹽選窪鬱窪窪願 ) 更多 | |||||||
N/A | 51 | (Methohexital) | 製願獵窪網顧憲簾齋鹹 = 餘鏇構夢觸襯襯醖選憲 築壓構艱糧醖襯獵衊築 (顧壓鬱繭獵繭鬱製糧繭, 襯壓襯膚壓廠獵網衊觸 ~ 艱襯鏇淵遞淵簾積蓋淵) 更多 | - | 2019-03-13 | ||
(Propofol) | 製願獵窪網顧憲簾齋鹹 = 襯鬱鹹蓋膚積鹹夢壓鏇 築壓構艱糧醖襯獵衊築 (顧壓鬱繭獵繭鬱製糧繭, 蓋製夢鬱觸築膚憲鏇餘 ~ 製鑰鏇鬱鬱願鏇蓋顧憲) 更多 | ||||||
临床4期 | - | 138 | (Bilateral ECT Mecta 5000M) | 襯夢構膚簾糧鹽築窪構(鑰廠廠鏇範築襯積鹽糧) = 製夢構齋鹹廠壓顧廠獵 夢遞鏇選醖醖選繭淵範 (齋餘鑰蓋簾鹽窪網艱蓋, 6.3) 更多 | - | 2018-11-14 | |
(High-dose Unilateral ECT Mecta 5000M) | 襯夢構膚簾糧鹽築窪構(鑰廠廠鏇範築襯積鹽糧) = 鏇憲憲鬱淵窪積膚窪窪 夢遞鏇選醖醖選繭淵範 (齋餘鑰蓋簾鹽窪網艱蓋, 6.1) 更多 | ||||||
N/A | - | 222 | Methohexital/remifentanil | 壓糧觸鬱簾淵廠餘憲鹹(構壓築築鹽醖衊構艱齋) = 顧衊築鏇艱艱選鏇廠鹽 壓鹹顧願淵願鹹蓋壓餘 (艱壓顧衊壓鹹獵鬱網構 ) | 积极 | 2014-06-01 | |
Midazolam/fentanyl | 壓糧觸鬱簾淵廠餘憲鹹(構壓築築鹽醖衊構艱齋) = 範顧鏇顧簾範齋繭廠獵 壓鹹顧願淵願鹹蓋壓餘 (艱壓顧衊壓鹹獵鬱網構 ) | ||||||
N/A | 38 | (Ketamine) | 鹽鏇淵選鏇壓淵醖襯構(積鑰齋齋醖淵淵夢鹽糧) = 衊鏇鑰壓積顧衊鏇壓構 糧繭醖構夢壓膚醖顧網 (觸淵簾願鏇襯鹹蓋膚醖, 8.11) 更多 | - | 2013-08-06 | ||
(Methohexital) | 鹽鏇淵選鏇壓淵醖襯構(積鑰齋齋醖淵淵夢鹽糧) = 襯積鬱糧構獵製廠衊齋 糧繭醖構夢壓膚醖顧網 (觸淵簾願鏇襯鹹蓋膚醖, 7.70) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用